The Irish Platform for Patient Organisations, Science, and Industry (IPPOSI) has announced the appointment of Laura Brady, PhD, as its new Chief Executive Officer, effective June 16, 2025.
IPPOSI said, “Laura brings over a decade of leadership experience across health innovation, patient advocacy, and academic research. Prior to joining IPPOSI, she was the Digital Health Innovation Lead at the FutureNeuro Research Centre for Translational Brain Science, where she successfully implemented a data and digital health strategy aimed at improving outcomes for individuals living with neurological and neuropsychiatric conditions.
“Previous to this role, Laura was the Head of Research at Fighting Blindness, where she spearheaded the organisation’s research strategy. She notably expanded the Target 5000 national patient registry, enhanced public and patient involvement in research, and generated evidence-based data that contributed to the reimbursement of Ireland’s first-ever gene therapy for a rare retinal disease.”
In addition to her professional achievements, Laura currently serves on the Board of HRCI – Health Research Charities Ireland and is a member of the National Genetics & Genomics Office (NGGO) PPI & Communications Working Group. She holds a PhD in Biochemistry from Trinity College Dublin and a Professional Diploma in Leading Digital Health Transformation from RCSI University of Medicine & Health Sciences.
“Laura is passionate about harnessing data, amplifying the patient voice, and fostering cross-sector collaboration to drive progress and unlock new opportunities in patient-centred healthcare innovation. We look forward to the impactful leadership Laura will bring to IPPOSI, and we are excited to continue our mission to advocate for patients and enhance healthcare outcomes in Ireland.”
